Tobin J Strom1, Andy M Trotti1, Julie Kish2, Jeffery S Russell3, Nikhil G Rao1, Judith McCaffrey3, Tapan A Padhya3, Kristen J Otto3, Jimmy J Caudell4. 1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 2. Department of Senior Adult Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 3. Department of Head and Neck and Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 4. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. Electronic address: Jimmy.Caudell@moffitt.org.
Abstract
BACKGROUND: Cisplatin dosed every 3 weeks (CIS) or weekly cetuximab (CTX) concurrent with radiotherapy are standards of care for locally advanced head and neck squamous cell carcinoma (LAHNC). Retrospective comparisons of CIS and CTX have offered mixed conclusions. We compared outcomes between CIS and CTX in this patient population. METHODS: Between January 2006 and December 2011, we identified 279 patients who underwent definitive radiotherapy and concurrent systemic therapy for LAHNC. The median age difference between the CIS and CTX groups was relatively small (58 vs. 62 years, respectively) and CIS patients had a slightly higher rate of N2 disease than CTX patients (74% vs. 61%, respectively). RESULTS: Median follow-up was 27 months. Systemic therapy consisted of CIS in 241 (86.4%) and CTX in 38 (13.6%). Actuarial locoregional control of the CIS and CTX groups at 2 years were 91% and 90% (p=0.74), respectively. Actuarial 2 year distant metastasis rates between the groups were 8% and 12%, respectively (p=0.55), and actuarial 2 year overall survival between the groups were 87% and 89%, respectively (p=0.47). CONCLUSIONS: We found no difference in locoregional control, distant metastasis rate, or overall survival between patients treated with concurrent CIS or CTX.
BACKGROUND:Cisplatin dosed every 3 weeks (CIS) or weekly cetuximab (CTX) concurrent with radiotherapy are standards of care for locally advanced head and neck squamous cell carcinoma (LAHNC). Retrospective comparisons of CIS and CTX have offered mixed conclusions. We compared outcomes between CIS and CTX in this patient population. METHODS: Between January 2006 and December 2011, we identified 279 patients who underwent definitive radiotherapy and concurrent systemic therapy for LAHNC. The median age difference between the CIS and CTX groups was relatively small (58 vs. 62 years, respectively) and CIS patients had a slightly higher rate of N2 disease than CTXpatients (74% vs. 61%, respectively). RESULTS: Median follow-up was 27 months. Systemic therapy consisted of CIS in 241 (86.4%) and CTX in 38 (13.6%). Actuarial locoregional control of the CIS and CTX groups at 2 years were 91% and 90% (p=0.74), respectively. Actuarial 2 year distant metastasis rates between the groups were 8% and 12%, respectively (p=0.55), and actuarial 2 year overall survival between the groups were 87% and 89%, respectively (p=0.47). CONCLUSIONS: We found no difference in locoregional control, distant metastasis rate, or overall survival between patients treated with concurrent CIS or CTX.
Authors: Shilpa Bhatia; Jaspreet Sharma; Sanjana Bukkapatnam; Ayman Oweida; Shelby Lennon; Andy Phan; Dallin Milner; Nomin Uyanga; Antonio Jimeno; David Raben; Hilary Somerset; Lynn Heasley; Sana D Karam Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: William A Stokes; Whitney A Sumner; Kiersten L Breggren; John T Rathbun; David Raben; Jessica D McDermott; Gregory Gan; Sana D Karam Journal: Rep Pract Oncol Radiother Date: 2017-08-02
Authors: Lova Sun; Danielle Candelieri-Surette; Tori Anglin-Foote; Julie A Lynch; Kara N Maxwell; Christopher D'Avella; Aditi Singh; Erin Aakhus; Roger B Cohen; Robert M Brody Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-09-22 Impact factor: 8.961
Authors: Arya Amini; Megan Eguchi; Bernard L Jones; William A Stokes; Abhinav Gupta; Jessica D McDermott; Erminia Massarelli; Cathy J Bradley; Sana D Karam Journal: Cancer Date: 2018-10-06 Impact factor: 6.860
Authors: James A Bonner; Jordi Giralt; Paul M Harari; Jose Baselga; Sharon Spencer; Diana Bell; David Raben; Joyce Liu; Jeltje Schulten; Kian K Ang; David I Rosenthal Journal: Eur J Cancer Date: 2016-06-17 Impact factor: 9.162
Authors: Loredana Vesci; Ferdinando Maria Milazzo; Anna Maria Anastasi; Fiorella Petronzelli; Caterina Chiapparino; Valeria Carollo; Giuseppe Roscilli; Emanuele Marra; Laura Luberto; Luigi Aurisicchio; Maria Lucrezia Pacello; Luigi Giusto Spagnoli; Rita De Santis Journal: Oncotarget Date: 2016-01-05